Kristin A Higgins1, Dongkyoo Park1, Gee Young Lee2, Walter J Curran1, Xingming Deng1. 1. Department of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia. 2. Department of Biomedical Engineering, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: It has been demonstrated that regular exercise improves the quality of life in patients undergoing treatment for lung cancer and has been associated with reductions in cancer-specific mortality in patients with colon and breast cancer. The direct effects of cardiovascular exercise on lung cancer tumor biology, however, remain unknown. The authors evaluated the effects of cardiovascular exercise in a mouse model of lung adenocarcinoma. METHODS: Luciferase-tagged A549 lung adenocarcinoma cells were injected through the tail vein of nude male mice. Then, the mice underwent weekly bioluminescent imaging until lung tumors were clearly identified. After lung tumors were identified, the mice were randomized to daily wheel running versus no wheel running, and they were imaged weekly. After 4 weeks, all mice were killed, and the lung tumors were harvested. Western blot and immunohistochemical analyses were conducted on tumor tissues to identify potential differences in protein expression levels in exercising mice versus sedentary mice. RESULTS: Lung tumors in exercising mice grew significantly more slowly relative to sedentary mice. There was no change in the development of metastatic lesions between the 2 groups. Protein analysis by Western blot or immunohistochemical analysis demonstrated increased p53 protein levels in exercising mice relative to sedentary mice as well as increased mediators of apoptosis, including Bax and active caspase 3, in tumor tissues. In both groups of mice, no normal tissue toxicity was observed in other organs. CONCLUSIONS: Daily cardiovascular exercise appears to mitigate the growth of lung adenocarcinoma tumors, possibly by activation of the p53 tumor suppressor function and increased apoptosis.
BACKGROUND: It has been demonstrated that regular exercise improves the quality of life in patients undergoing treatment for lung cancer and has been associated with reductions in cancer-specific mortality in patients with colon and breast cancer. The direct effects of cardiovascular exercise on lung cancer tumor biology, however, remain unknown. The authors evaluated the effects of cardiovascular exercise in a mouse model of lung adenocarcinoma. METHODS: Luciferase-tagged A549 lung adenocarcinoma cells were injected through the tail vein of nude male mice. Then, the mice underwent weekly bioluminescent imaging until lung tumors were clearly identified. After lung tumors were identified, the mice were randomized to daily wheel running versus no wheel running, and they were imaged weekly. After 4 weeks, all mice were killed, and the lung tumors were harvested. Western blot and immunohistochemical analyses were conducted on tumor tissues to identify potential differences in protein expression levels in exercising mice versus sedentary mice. RESULTS:Lung tumors in exercising mice grew significantly more slowly relative to sedentary mice. There was no change in the development of metastatic lesions between the 2 groups. Protein analysis by Western blot or immunohistochemical analysis demonstrated increased p53 protein levels in exercising mice relative to sedentary mice as well as increased mediators of apoptosis, including Bax and active caspase 3, in tumor tissues. In both groups of mice, no normal tissue toxicity was observed in other organs. CONCLUSIONS: Daily cardiovascular exercise appears to mitigate the growth of lung adenocarcinoma tumors, possibly by activation of the p53tumor suppressor function and increased apoptosis.
Authors: Jeffrey A Meyerhardt; Denise Heseltine; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; James Thomas; Heidi Nelson; Renaud Whittom; Alexander Hantel; Richard L Schilsky; Charles S Fuchs Journal: J Clin Oncol Date: 2006-07-05 Impact factor: 44.544
Authors: A Ashkenazi; R C Pai; S Fong; S Leung; D A Lawrence; S A Marsters; C Blackie; L Chang; A E McMurtrey; A Hebert; L DeForge; I L Koumenis; D Lewis; L Harris; J Bussiere; H Koeppen; Z Shahrokh; R H Schwall Journal: J Clin Invest Date: 1999-07 Impact factor: 14.808
Authors: T Takahashi; M M Nau; I Chiba; M J Birrer; R K Rosenberg; M Vinocour; M Levitt; H Pass; A F Gazdar; J D Minna Journal: Science Date: 1989-10-27 Impact factor: 47.728
Authors: Olivia Fletcher; Lorna Gibson; Nichola Johnson; Dan R Altmann; Jeffrey M P Holly; Alan Ashworth; Julian Peto; Isabel Dos Santos Silva Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-01 Impact factor: 4.254
Authors: Scott J Strath; Leonard A Kaminsky; Barbara E Ainsworth; Ulf Ekelund; Patty S Freedson; Rebecca A Gary; Caroline R Richardson; Derek T Smith; Ann M Swartz Journal: Circulation Date: 2013-10-14 Impact factor: 29.690
Authors: Iwona Malicka; Katarzyna Siewierska; Bartosz Pula; Christopher Kobierzycki; Dominik Haus; Urszula Paslawska; Marek Cegielski; Piotr Dziegiel; Marzena Podhorska-Okolow; Marek Wozniewski Journal: Exp Biol Med (Maywood) Date: 2015-05-19
Authors: M Pollán; S Casla-Barrio; J Alfaro; C Esteban; M A Segui-Palmer; A Lucia; M Martín Journal: Clin Transl Oncol Date: 2020-02-13 Impact factor: 3.405
Authors: Scott A Fisher; Carolyn J Peddle-McIntyre; Kimberley Burton; Robert U Newton; Elly Marcq; Richard A Lake; Anna K Nowak Journal: BMC Res Notes Date: 2020-09-15